Drug Trial Radar · NCT04699591
Compassionate Use of Domperidone for Refractory Gastroparesis
Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Apr 2013
Primary completion
Dec 2035
Study completion Dec 2035
Sponsor
- Lead sponsor
- Jose CocjinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 7, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.
Conditions
- GERD
- Gastroesophageal Reflux
- Gastroparesis
Interventions
DomperidoneDrug
Domperidone taken 4 times a day, dose based on body weight
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in disease severityTime frame: Up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Mercy Hospitals and Clinics
Kansas City, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.